Medication

Ozempic vs Mounjaro: Which Weight Loss Drug Works Better — The Head-to-Head Data

By Health 656 Editorial Team 2026-03-31 10 min read

Medical injection pen for weight loss medication

Two drugs have changed the obesity conversation forever. Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are GLP-1 based medications that produce weight loss previously achievable only through surgery. The SURMOUNT-1 trial found that tirzepatide produced 22.5 percent body weight loss at the highest dose — roughly 52 pounds for a 230-pound person. The STEP 1 trial found semaglutide produced 14.9 percent. Both are prescription medications with significant costs, side effects, and questions about what happens when you stop. With millions of prescriptions written and a $50 billion market projected by 2030, the hype is enormous. This guide presents the head-to-head comparison based on published clinical trials — not marketing.

How They Work — Same Family, Different Mechanism

Both drugs mimic gut hormones that regulate appetite and blood sugar. Semaglutide targets one receptor: GLP-1 (glucagon-like peptide-1). GLP-1 slows gastric emptying (food stays in the stomach longer, making you feel full), reduces appetite through brain signaling in the hypothalamus, and improves insulin secretion. Tirzepatide targets two receptors: GLP-1 plus GIP (glucose-dependent insulinotropic polypeptide). GIP adds additional appetite suppression and may enhance fat metabolism. This dual mechanism is likely why tirzepatide produces greater weight loss.

Both are weekly injections — a small needle into the abdomen, thigh, or upper arm. Both require dose escalation over weeks to months to minimize GI side effects. Semaglutide: 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg (Wegovy). Tirzepatide: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg.

The Data — Weight Loss Comparison

Semaglutide 2.4mg (Wegovy) — STEP 1 trial: 1,961 adults without diabetes. 14.9 percent body weight loss at 68 weeks (~34 pounds for a 230-pound person). 32 percent of participants lost 20 percent or more of body weight. Tirzepatide 15mg (Zepbound) — SURMOUNT-1 trial: 2,539 adults without diabetes. 22.5 percent body weight loss at 72 weeks (~52 pounds for a 230-pound person). 63 percent lost 20 percent or more.

The SURMOUNT-5 trial — the first direct head-to-head comparison — found that tirzepatide 15mg produced 20.2 percent weight loss versus 13.7 percent for semaglutide 2.4mg at 72 weeks. Tirzepatide won convincingly on weight loss magnitude.

Both drugs also improve cardiovascular risk markers: blood pressure drops 5-8 mmHg, triglycerides decrease 20-25 percent, A1C drops 1.5-2.0 percent in diabetic patients, and waist circumference decreases significantly. The SELECT trial proved that semaglutide reduced major cardiovascular events by 20 percent in people with obesity and established heart disease — a landmark finding.

Side Effects — The Reality Nobody Likes Discussing

Both drugs share GI side effects because they slow gastric emptying. Nausea (30-45 percent of patients — usually worst during dose escalation and improves over weeks), vomiting (15-25 percent), diarrhea (15-20 percent), constipation (10-15 percent), and abdominal pain. Most side effects are mild-to-moderate and diminish with time. Slow dose escalation is the key — rushing the titration dramatically worsens GI tolerance.

More concerning side effects: Muscle loss: Roughly 25 to 40 percent of weight lost on GLP-1 drugs is lean mass (muscle), not fat. A study in the NEJM found that semaglutide users lost an average of 8 pounds of lean mass alongside 25 pounds of fat. High protein intake (1.2-1.6g/kg) and resistance training during treatment preserve muscle — but many patients are not counseled on this. Pancreatitis: Rare but reported — roughly 0.1 to 0.3 percent in clinical trials. Gallstones: Rapid weight loss increases gallstone risk — reported in 1-2 percent of trial participants. Thyroid C-cell tumors: Seen in rodent studies at high doses — human risk is uncertain. Both drugs carry a boxed warning for medullary thyroid carcinoma risk and are contraindicated in patients with personal or family history of MTC or MEN2.

A 48-year-old accountant started tirzepatide and lost 45 pounds in 8 months. She was thrilled. But she did no resistance training and ate only 1,000 calories daily because of suppressed appetite. A DEXA scan revealed she had lost 18 pounds of muscle along with 27 pounds of fat. Her metabolic rate had dropped accordingly. Her endocrinologist increased her protein to 120g daily and started a twice-weekly strength program. "Nobody told me the drug could eat my muscles along with my fat," she said.

What Happens When You Stop — The Rebound Problem

This is the question everyone asks and nobody wants to answer honestly. The STEP 1 extension trial found that participants who stopped semaglutide regained two-thirds of the weight they had lost within one year of discontinuation. The biological mechanisms that drove weight regain before the drug — reduced leptin, increased ghrelin, metabolic adaptation — return the moment the drug is stopped. The medication suppresses these signals; it does not reset them.

This means for most patients, GLP-1 drugs are a long-term (potentially lifelong) commitment — similar to blood pressure or cholesterol medication. Stopping means the condition returns. This has enormous cost implications — semaglutide lists at roughly $1,000-1,300/month and tirzepatide at $1,000-1,100/month without insurance. Some insurance plans cover them for diabetes but not for weight loss alone.

The most honest framing: these drugs are remarkably effective at producing weight loss that was previously unachievable for most people. But they are not a cure — they are ongoing treatment for a chronic biological condition. Lifestyle changes (high protein, resistance training, sleep, stress management) during treatment maximize results and may reduce the rebound if medication is eventually stopped.

Common Questions

Which is better — Ozempic or Mounjaro?

For weight loss alone, tirzepatide (Mounjaro/Zepbound) produces significantly more weight loss — 20-22 percent versus 14-15 percent in trials. For cardiovascular protection, semaglutide (Ozempic/Wegovy) has the SELECT trial proving a 20 percent reduction in cardiac events. The choice depends on your primary goal and insurance coverage.

Can I take these drugs if I am not diabetic?

Yes. Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved specifically for weight management in adults with BMI above 30, or BMI above 27 with a weight-related condition. Ozempic and Mounjaro are approved for diabetes — using them for weight loss alone is off-label.

Will I regain the weight when I stop?

Studies show that roughly two-thirds of lost weight is regained within a year of stopping. These medications suppress appetite-driving hormones; they do not reset them. Most experts consider GLP-1 drugs a long-term treatment, similar to blood pressure medication — stopping means the condition returns.

How do I prevent muscle loss on these drugs?

Eat at least 1.2 to 1.6 grams of protein per kilogram of body weight daily. Perform resistance training at least twice weekly. Do not eat below 1,200 calories — the appetite suppression can make you eat too little, accelerating muscle loss. Ask your doctor about monitoring lean mass with DEXA scans.

ozempic mounjaro tirzepatide semaglutide GLP-1 weight-loss diabetes

Supplements

How to Read Your Cholesterol Numbers: What LDL, HDL, and Triglycerides Actually Mean

2026-04-04 10 min read